

INVENTOR SEARCH

-- fil capl; d que nos 144

FILE 'CAPLUS' ENTERED AT 15:08:14 ON 15 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGE/TERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jun 2007 VOL 146 ISS 26

FILE LAST UPDATED: 14 Jun 2007 (20070614/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OSI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L5 STR
L11 625 SRA FILE-REGISTRY SSS PUL L5
L21 1 SRA FILE-CAPLUS ADD-ON US2005-561415/AP
L35 STR
L38 STR
L39 STR
L42 151 SRA FILE-REGISTRY SUB-L11 SSS PUL (L35 OR L38 OR L39)
L43 5 SRA FILE-CAPLUS ADD-ON L42
L44 1 SRA FILE-CAPLUS ADD-ON L21 OR (L21 AND L43)

-- d ibid abe hitstr 144

L44 ABSTRACT 1 OF 1 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 2005-1434-S CAPLUS FULL-TEXT
PUBLICATION NUMBER: 1434-3337
TITLE: Preparation of benzophenone derivatives as HSP90 inhibitors for treatment of tumor
INVENTOR(S): Mori, Shinji; Nakagawa, Hisashi; Yanda, Yutaka; Nakashima, Takayuki; Goto, Shiro; Kajita, Jiro; Sakai, Jun-ichi; Shiota, Takamasa; Akimaga, Shiro
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: J. Pharm. Med. 196 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

NO 2005-060773 A 20050106 WO 2004-078494 20040616
W: AP, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, CA, CC, CD, CE, CF, CG, CH, CI, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GR, GU, HK, HN, HU, IL, IN, JP, KE, KG, KH, KR, KZ, LA, LB, LC, LI, LU, LV, MA, MD, ME, MG, MK, MN, MU, MV, MY, NA, NE, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, QA, RO, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, SV, SW, SY, TD, TH, TM, TN, TR, TZ, UA, UG, US, UZ, VC, VE, VN, YU, ZA, ZM, ZW
NW: AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AM, AN, AO, AP, AQ, AR, AS, AT, AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DA, DB, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LL, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ


AB 2004291949 A1 20050104 AU 2004-111149 20040410
CA 2559371 A1 20050104 CA 2004-291949 20040610
EP 1642893 A1 20050303 EP 2004-749232 20040610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, SK, SI, TR, CY, FI, HU, NO, PT, RU, UA, UK, US, JP, KR, CN, TW, AU, NZ, BR, AR, CL, CO, EC, EG, IL, IN, IS, JP, KE, KG, KH, KR, KZ, LA, LB, LC, LI, LU, LV, MA, MD, ME, MG, MK, MN, MU, MV, MY, NA, NE, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ

PRIORITY CLAIM: INTEL: A1 20050303 JP 2004-17475 A 20040410
WO 2004-078494 W 20040610

OPEN SEARCH(S): MARPAT 1434337

XP Entered STN: 07 Jan 2005


OF




AR This title compds. I (wherein n = 1-10; R1 = H, OH, CN, etc.; R2 = (unsubstituted alkyl, alkynyl, alkenyl, cycloalkyl, aryl, or heteroaryl); R3 and R4 = independently H, OH, CN, etc.) or prodrug or pharmaceutically acceptable salts thereof are provided as heat-shock protein (HSP) 90 inhibitors. For example, the compound II was prepared as a multi-step synthesis. It inhibited J30 human HSP90 at the concentration of 10 μM. It was useful as antitumor agents (see text).

IT 019011-02-2P 019012-04-5P
EL: DAC (Pharmacological activity); RCT (Reaction); GPH (Synthetic preparation); THU (Therapeutic use); BGL (Biological study); PREP (Preparation); RCT (Reaction or reagent); USGS (Use);
[Drug candidate; preparation of benzophenone deriva. as HSP90 inhibitors for treatment of tumor]

EN 019011-02-2P CAPLUS
CN Benzophenoneamide, N-[2-(dimethylamino)ethyl]-2-ethyl-3,5-dihydroxy-4-(4-methoxybenzoyl)-N-methyl- (9CI) (CA INDEX NAME)




PH 019012-04-5P CAPLUS
CN Benzophenoneamide, 2-ethyl-3,5-dihydroxy-N,N-bis[2-(methoxyethyl)-6-(4-methoxy-4-[2-(4-morpholinyl)ethyl]benzoyl)- (9CI) (CA INDEX NAME)




IT 019010-09-4P 019010-02-5P 019010-03-0P
019010-05-2P 019010-04-3P 019011-00-2P
019011-01-3P 019011-02-4P 019011-03-5P
019011-04-6P 019011-05-7P 019011-07-9P
019011-09-1P 019011-10-4P 019011-11-5P
019011-12-6P 019011-14-9P 019011-15-9P
019011-16-0P 019011-17-1P 019011-18-2P
019011-19-3P 019011-20-4P 019011-21-5P
019011-22-6P 019011-23-7P 019011-24-8P
019011-25-9P 019011-26-0P 019011-27-1P
019011-28-2P 019011-29-3P 019011-30-4P
019011-31-5P 019011-32-6P 019011-33-7P
019011-34-8P 019011-35-9P 019011-36-0P
019011-37-1P 019011-38-2P 019011-39-3P
019011-40-4P 019011-41-5P 019011-42-6P
019011-43-7P 019011-44-8P 019011-45-9P
019011-46-0P 019011-47-1P 019011-48-2P
019011-49-3P 019011-50-4P 019011-51-5P
019011-52-6P 019011-53-7P 019011-54-8P
019011-55-9P 019011-56-0P 019011-57-1P
019011-58-2P 019011-59-3P 019011-60-4P
019011-61-5P 019011-62-6P 019011-63-7P
019011-64-8P 019011-65-9P 019011-66-0P
019011-67-1P 019011-68-2P 019011-69-3P
019011-70-4P 019011-71-5P 019011-72-6P
019011-73-7P 019011-74-8P 019011-75-9P
019011-76-0P 019011-77-1P 019011-78-2P
019011-79-3P 019011-80-4P 019011-81-5P
019011-82-6P 019011-83-7P 019011-84-8P
019011-85-9P 019011-86-0P 019011-87-1P
019011-88-2P 019011-89-3P 019011-90-4P
019011-91-5P 019011-92-6P 019011-93-7P
019011-94-8P 019011-95-9P 019011-96-0P
019011-97-1P 019011-98-2P 019011-99-3P
019012-00-4P 019012-01-5P 019012-02-6P
019012-03-7P 019012-04-8P 019012-05-9P
019012-06-0P 019012-07-1P 019012-08-2P
019012-09-3P 019012-10-4P 019012-11-5P
019012-12-6P 019012-13-7P 019012-14-8P
019012-15-9P 019012-16-0P 019012-17-1P
019012-18-2P 019012-19-3P 019012-20-4P

019012-21-0P 019012-22-1P 019012-23-2P
019012-24-3P 019012-25-4P 019012-26-5P
019012-27-6P 019012-28-7P 019012-29-8P
019012-30-9P 019012-31-0P
R: DAC (Pharmacological activity); THU (Therapeutic use); BGL (Biological study); PREP (Preparation); RCT (Reaction or reagent); USGS (Use);
[Drug candidate; preparation of benzophenone deriva. as HSP90 inhibitors for treatment of tumor]


EN 019012-04-5P CAPLUS
CN Benzophenoneamide, 2-ethyl-3,5-dihydroxy-N,N-bis[2-(hydroxyethyl)-6-(4-methoxybenzoyl)-N-methyl- (9CI) (CA INDEX NAME)





PH 019012-04-5P CAPLUS
CN Benzophenoneamide, 2-ethyl-3,5-dihydroxy-N,N-bis[2-(hydroxyethyl)-6-(4-methoxybenzoyl)-N-methyl- (9CI) (CA INDEX NAME)



PH 019012-04-5P CAPLUS
CN Benzophenoneamide, 2-ethyl-3,5-dihydroxy-N,N-bis[2-(hydroxyethyl)-6-(4-methoxybenzoyl)-N-methyl- (9CI) (CA INDEX NAME)




PH 019012-04-5P CAPLUS
CN Benzophenoneamide, 2-ethyl-3,5-dihydroxy-N,N-bis[2-(hydroxyethyl)-6-(4-methoxybenzoyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 519810-96-3 CAPLUS

CH Piperazine, 1-[(2-cyanophenyl)-4-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 519811-00-2 CAPLUS

CH 3-Piperidindiol, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 519811-01-3 CAPLUS

CH 3-Piperidindiol, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 519811-02-4 CAPLUS

CH 7-Piperidinoacetamide, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 519811-03-5 CAPLUS

CH 4-Piperidinoacetamide, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 519811-04-6 CAPLUS

CH 7-Piperidindiol, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]- (9CI) (CA INDEX NAME)



RN 519811-05-7 CAPLUS



CH Butanoacetamide, N-[(2,3-dihydroxypropyl)-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-methyl]- (9CI) (CA INDEX NAME)



RN 519811-07-9 CAPLUS


CH Butanoacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(3-

pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 519811-09-1 CAPLUS

CH Piperazine, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 519811-10-1 CAPLUS

CH 4-Piperidindiol, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 519811-11-3 CAPLUS

CH Piperazine, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-4-(2-pyridindiolyl)- (9CI) (CA INDEX NAME)




RN 519811-12-6 CAPLUS

CH Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 519811-14-8 CAPLUS

CH Piperazine, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-4-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 519811-15-9 CAPLUS

CH Piperazine, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 519811-16-0 CAPLUS

CH Piperazine, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 519811-17-1 CAPLUS

CM Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenylacetate
1,2,3,4-tetrahydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)




PM 519811-15-2 CAPLUS

CM Benzeneacetamide, 2-ethyl-N-[(2-furylmethyl)-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetate (9CI) (CA INDEX NAME)




PM 519811-15-3 CAPLUS

CM 1-Piperazineethanol, 4-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetate] (9CI) (CA INDEX NAME)




PM 519811-15-6 CAPLUS

CM Piperazine, 1-[[2-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetate]-1-phenyl] (9CI) (CA INDEX NAME)




PM 519811-21-7 CAPLUS

CM Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




PM 519811-22-8 CAPLUS

CM Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetate]-4-[[3-hydroxyphenyl] (9CI) (CA INDEX NAME)



PM 519811-23-9 CAPLUS


CM Morpholine, 4-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetate] (9CI) (CA INDEX NAME)



PM 519811-24-0 CAPLUS


CM Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-[(1,2-oxo-1-

pyrrolidinyl)propyl] (9CI) (CA INDEX NAME)




PM 519811-25-1 CAPLUS

CM Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-oxo-1-pyrrolidinyl)propyl] (9CI) (CA INDEX NAME)




PM 519811-25-2 CAPLUS

CM Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-oxo-1-pyrrolidinyl)propyl] (9CI) (CA INDEX NAME)




PM 519811-25-3 CAPLUS

CM Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-oxo-1-pyrrolidinyl)propyl] (9CI) (CA INDEX NAME)




PM 519811-25-3 CAPLUS

CM Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-oxo-1-pyrrolidinyl)propyl] (9CI) (CA INDEX NAME)




PM 519811-25-1 CAPLUS

CM Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-oxo-1-pyrrolidinyl)propyl] (9CI) (CA INDEX NAME)




PM 519811-25-2 CAPLUS

CM Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-oxo-1-pyrrolidinyl)propyl] (9CI) (CA INDEX NAME)




PM 519811-25-3 CAPLUS


CM Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-oxo-1-pyrrolidinyl)propyl] (9CI) (CA INDEX NAME)




RN 619811-43-2 CAPLUS
 CN 4-Piperidinomethanol, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]- (PCI) (CA INDEX NAME)




RN 619811-43-3 CAPLUS
 CN Piperazinone, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]- (PCI) (CA INDEX NAME)



RN 619811-43-5 CAPLUS
 CN Benzeneacetamide, 2-ethyl-4-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (PCI) (CA INDEX NAME)




RN 619811-43-6 CAPLUS
 CN Piperidine, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (PCI) (CA INDEX NAME)




13


RN 619811-47-2 CAPLUS
 CN Piperazinone, 1-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-1-phenyl- (PCI) (CA INDEX NAME)




RN 619811-47-4 CAPLUS
 CN Benzeneacetamide, 2-ethyl-4-[(2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl)acetyl]-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (PCI) (CA INDEX NAME)



RN 619811-54-6 CAPLUS
 CN Piperazinone, 4-[(2-benzoyl-6-ethyl-3,5-dihydroxyphenyl)acetyl]-1-(2-cyanoethyl)- (PCI) (CA INDEX NAME)




RN 619811-55-7 CAPLUS
 CN Benzeneacetamide, 2-benzoyl-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (PCI) (CA INDEX NAME)




14


RN 619811-54-8 CAPLUS
 CN Benzeneacetamide, 2-benzoyl-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (PCI) (CA INDEX NAME)




RN 619811-54-9 CAPLUS
 CN 4-Piperidinomethanol, 1-[(2-benzoyl-6-ethyl-3,5-dihydroxyphenyl)acetyl]-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (PCI) (CA INDEX NAME)



RN 619811-54-9 CAPLUS
 CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (PCI) (CA INDEX NAME)




RN 619811-54-1 CAPLUS
 CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-bis(2-hydroxyethyl)- (PCI) (CA INDEX NAME)




15


RN 619811-50-4 CAPLUS
 CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (PCI) (CA INDEX NAME)



RN 619811-61-8 CAPLUS
 CN Piperazinone, 1-[(2-ethyl-3,5-dihydroxyphenyl)acetyl]-1-phenyl- (PCI) (CA INDEX NAME)




RN 619811-62-6 CAPLUS
 CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(2-hydroxy-4-methoxybenzoyl)- (PCI) (CA INDEX NAME)



RN 619811-63-7 CAPLUS
 CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(2-hydroxy-4-methoxybenzoyl)-N-(2-methoxyethyl)- (PCI) (CA INDEX NAME)




16




RN 819611-64-3 CASLUG

CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-trifluoromethoxyphenyl)-6-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)




RN 819611-65-2 CASLUG

CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-trifluoromethoxyphenyl)-6-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)



RN 819611-66-4 CASLUG


CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-trifluoromethoxyphenyl)-6-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)



RN 819611-67-3 CASLUG


CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-trifluoromethoxyphenyl)-6-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)

17




RN 819611-68-5 CASLUG

CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-trifluoromethoxyphenyl)-6-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)




RN 819611-69-3 CASLUG

CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-trifluoromethoxyphenyl)-6-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)



RN 819611-70-6 CASLUG


CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-trifluoromethoxyphenyl)-6-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)



RN 819611-71-7 CASLUG


CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-trifluoromethoxyphenyl)-6-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)

18




RN 819611-72-3 CASLUG

CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-trifluoromethoxyphenyl)-6-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)




RN 819611-73-5 CASLUG

CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-trifluoromethoxyphenyl)-6-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)




RN 819611-74-9 CASLUG

CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-trifluoromethoxyphenyl)-6-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)




RN 819611-75-1 CASLUG

CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-trifluoromethoxyphenyl)-6-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)



RN 819611-76-2 CASLUG


CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-trifluoromethoxyphenyl)-6-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)



RN 819611-77-3 CASLUG


CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-trifluoromethoxyphenyl)-6-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 819611-78-4 CASLUG

CN Benzenesacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-trifluoromethoxyphenyl)-6-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)




RN 819611-79-3 CASLUG

19


20

RN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)




RN 819811-47-8 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)




RN 819811-41-9 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)




RN 819811-82-0 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)




RN 819811-43-1 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)




RN 819811-84-2 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)




RN 819811-85-3 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)




RN 819811-86-4 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-methoxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)




RN 819811-67-5 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)




RN 819811-88-6 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)




RN 819811-89-7 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)




RN 819811-66-4 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)




RN 819811-61-1 CAPLUS

CN Benzeneacetamide, 2-[(3,4-dimethoxyphenyl)-N-[(2-methoxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)



RN 819811-92-3 CAPLUS


CN Benzeneacetamide, N-[(2-methoxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)



RN 819811-96-4 CAPLUS


CN Benzeneacetamide, N-[(2-methoxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)






RN 619811-96-5 CASREG

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-4-[(4-methoxyphenyl)-N-(2-methoxyethyl)-N-[2-(4-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 619811-96-6 CASREG

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxypropyl)-6-[(4-methoxyphenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619811-97-7 CASREG

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-4-[(4-methoxyphenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 619811-98-6 CASREG

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-bis(2-hydroxyethyl)-6-[(4-methoxyphenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)


25

Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-bis(2-hydroxyethyl)-6-[(4-methoxyphenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 619811-99-5 CASREG

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-bis(2-hydroxyethyl)-6-[(4-methoxyphenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 619811-00-5 CASREG

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-bis(2-hydroxyethyl)-6-[(4-methoxyphenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619811-01-6 CASREG


CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-bis(2-hydroxyethyl)-6-[(4-methoxyphenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619811-02-7 CASREG


CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-bis(2-hydroxyethyl)-6-[(4-methoxyphenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)

26




RN 619811-03-7 CASREG

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-bis(2-hydroxyethyl)-6-[(4-methoxyphenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 619811-04-8 CASREG

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-bis(2-hydroxyethyl)-6-[(4-methoxyphenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 619811-05-9 CASREG

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-bis(2-hydroxyethyl)-6-[(4-methoxyphenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 619811-06-0 CASREG

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-bis(2-hydroxyethyl)-6-[(4-methoxyphenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 619811-06-1 CASREG

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-bis(2-hydroxyethyl)-6-[(4-methoxyphenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 619811-07-2 CASREG

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-bis(2-hydroxyethyl)-6-[(4-methoxyphenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 619811-08-3 CASREG

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-bis(2-hydroxyethyl)-6-[(4-methoxyphenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 619811-09-4 CASREG

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-bis(2-hydroxyethyl)-6-[(4-methoxyphenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)


27

28




RN 819612-11-2 CASLUS

CN Benzenesacetamide, 2-(4-ethoxyphenyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 819612-13-3 CASLUS

CN Benzenesacetamide, 2-ethyl-1,5-dihydroxy-N-(2-methoxyethyl)-N-[2-(4-methoxyphenyl)ethyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 819612-14-1 CASLUS

CN Benzenesacetamide, 2-ethyl-1,5-dihydroxy-N-(2-methoxyethyl)-N-[2-(4-methoxyphenyl)ethyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 819612-15-2 CASLUS

CN Benzenesacetamide, 2-ethyl-1,5-dihydroxy-N-(2-methoxyethyl)-N-[2-(4-methoxyphenyl)ethyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 819612-16-3 CASLUS

CN Benzenesacetamide, 2-(3,4-dihydroxyphenyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 819612-17-4 CASLUS

CN Benzenesacetamide, 2-(3,4-dihydroxyphenyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 819612-18-5 CASLUS

CN Benzenesacetamide, 2-ethyl-1,5-dihydroxy-N-bis(2-methoxyethyl)-N-[2-methoxy-4-(2-(4-morpholinyl)ethoxy)benzoyl]-monohydrochloride (9CI) (CA INDEX NAME)




RN 819612-19-6 CASLUS

CN Benzenesacetamide, N-[2-(dimethylamino)ethyl]-2-ethyl-3,5-dihydroxy-4-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819612-20-3 CASLUS

CN Benzenesacetamide, 2-(3,4-dimethoxyphenyl)-6-ethyl-3,5-dihydroxy-N-bis(2-methoxyethyl)-N-[2-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 819612-21-0 CASLUS


CN Benzenesacetamide, N-[2-(dimethylamino)ethyl]-2-ethyl-3,5-dihydroxy-4-(4-methoxybenzoyl)-N-(2-methoxyethyl)-monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 819612-22-1 CASLUS

CN Benzenesacetamide, 2-ethyl-1,5-dihydroxy-N-bis(2-hydroxyethyl)-N-[4-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 819612-23-2 CASLUS

CN Benzenesacetamide, 2-ethyl-1,5-dihydroxy-N-(2-methoxyethyl)-N-(2-methoxyethyl)-6-[4-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 819612-24-3 CASLUS

CN Benzenesacetamide, 2-(3,4-difluorophenyl)-6-ethyl-3,5-dihydroxy-N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819612-25-4 CASLUS

CN Benzenesacetamide, 2-(3,4-difluorophenyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819612-26-5 CASLUS

CN Benzenesacetamide, 2-ethyl-1,5-dihydroxy-N-bis(2-methoxyethyl)-N-[4-methoxy-4-(2-(4-piperidinyl)ethoxy)benzoyl]- (9CI) (CA INDEX NAME)




BN 11512-21-6 CASLUG

CN Benzeneacetamide, 2-ethyl-1,3-dihydroxy-N,N-bis[2-methoxyethyl]-6-(3-methoxy-4-[2-[(4-methyl-1-piperidinyl)propoxy]benzoyl]-5-hydroxyethyl)- (9CI) (CA INDEX NAME)




BN 115613-29-7 CASLUG

CN Benzeneacetamide, 2-ethyl-1,3-dihydroxy-N,N-bis[2-methoxyethyl]-6-(3-methoxy-4-[2-[(4-morpholinyl)propoxy]benzoyl]-5-hydroxyethyl)- (9CI) (CA INDEX NAME)




BN 115613-29-7 CASLUG

CN Benzeneacetamide, 2-ethyl-1,3-dihydroxy-N,N-bis[2-methoxyethyl]-6-(3-methoxy-4-[2-[(4-methyl-1-piperidinyl)propoxy]benzoyl]-5-hydroxyethyl)- (9CI) (CA INDEX NAME)




BN 115613-36-7 CASLUG

CN Benzeneacetamide, 2-ethyl-1,3-dihydroxy-N,N-bis[2-methoxyethyl]-6-(3-methoxy-4-[2-[(4-morpholinyl)propoxy]benzoyl]-5-hydroxyethyl)- (9CI) (CA INDEX NAME)



BN 115613-37-8 CASLUG

CN Benzeneacetamide, 2-ethyl-1,3-dihydroxy-N,N-bis[2-methoxyethyl]-6-(3-methoxy-4-[2-[(4-morpholinyl)propoxy]benzoyl]-5-hydroxyethyl)- (9CI) (CA INDEX NAME)



IT 115613-53-4P 115613-12-2P 115613-17-7P

115613-18-8P 115613-30-4P 115613-40-6P

115613-45-1P 115613-47-3P 115613-48-4P

115613-49-5P 115613-50-8P 115613-51-9P

115613-56-4P 115613-57-5P 115613-58-6P

115613-59-7P 115613-60-8P 115613-61-1P

115613-62-2P 115613-63-3P 115613-64-4P

115613-67-7P 115613-69-9P 115613-70-2P

115613-78-0P 115613-73-1P 115613-80-4P

115613-81-5P 115613-82-6P 115613-83-7P



115613-84-8P

RU: RCT (Reactant); SYN (Synthetic preparation); PREP (Preparation); RACT (Reactant or Reagent)

[antitumor, preparation of benzophenone derivs. as VGP-6 analogs for treatment of tumor]

BN 115613-93-6 CASLUG


CN Piperazine, 1-[2-ethyl-6-(4-hydroxybenzoyl)-3,5-bis[2-propenyl]oxy]phenylacetyl-4-phenyl- (9CI) (CA INDEX NAME)



BN 115613-12-2 CASLUG


CN Benzeneacetamide, 2-ethyl-6-(4-hydroxybenzoyl)-N-[2-hydroxyethyl]-N-(2-

methoxyethyl]-3,5-bis[2-propenyl]oxy- (9CI) (CA INDEX NAME)




BN 115613-17-7 CASLUG

CN Benzeneacetamide, 2-ethyl-6-(4-hydroxybenzoyl)-N-[2-hydroxyethyl]-N-(2-methoxyethyl)-3,5-bis[2-propenyl]oxy- (9CI) (CA INDEX NAME)




BN 115613-17-7 CASLUG

CN Benzeneacetamide, 2-ethyl-6-(4-hydroxybenzoyl)-N-[2-hydroxyethyl]-N-(2-methoxyethyl)-3,5-bis[2-propenyl]oxy- (9CI) (CA INDEX NAME)




BN 115613-37-8 CASLUG

CN Benzeneacetamide, 2-ethyl-6-(4-hydroxybenzoyl)-N-[2-hydroxyethyl]-N-(2-methoxyethyl)-3,5-bis[2-propenyl]oxy- (9CI) (CA INDEX NAME)




BN 115613-47-9 CASLUG

CN Benzeneacetamide, 2-ethyl-6-(4-hydroxybenzoyl)-N-[2-hydroxyethyl]-N-(2-methoxyethyl)-3,5-bis[2-propenyl]oxy- (9CI) (CA INDEX NAME)




BN 115613-45-1 CASLUG

CN Benzeneacetamide, 2-ethyl-6-(4-hydroxybenzoyl)-N-[2-methoxyethyl]-N-(2-(4-morpholinyl)ethyl)-3,5-bis[2-propenyl]oxy- (9CI) (CA INDEX NAME)




BN 115613-47-9 CASLUG

CN Benzeneacetamide, 2-[3,4-dimethoxybenzoyl]-N-[2-(dimethylamino)ethyl]-6-ethyl-N-(2-methoxyethyl)-3,5-bis[2-propenyl]oxy- (9CI) (CA INDEX NAME)




BN 115613-48-4 CASLUG

CN Benzeneacetamide, 2-[2-(dimethylamino)ethyl]-6-ethyl-N-(2-methoxyethyl)-N-[2-methoxyethyl]-3,5-bis[2-propenyl]oxy- (9CI) (CA INDEX NAME)




BN 115613-47-9 CASLUG

RU Benzeneacetamide, 2-ethyl-6-[(4-dimethylaminophenyl)-2-(3,4-dimethoxybenzoyl)-6-ethyl-N-(2-propenyloxy)ethyl]-3,5-bis(2-propenyloxy)- (PCI) (CA INDEX NAME)




RU 11513-57-3 CAPLUS

CN Benzeneacetamide, 2-ethyl-6-[(4-dimethoxybenzoyl)-6-ethyl-N-(2-methoxyethyl)-N-(2-morpholinoethyl)ethyl]-3,5-bis(2-propenyloxy)- (PCI) (CA INDEX NAME)




RU 11513-51-9 CAPLUS

CN Benzeneacetamide, 2-ethyl-6-[(4-methoxybenzoyl)-N-(2-methoxyethyl)-N-(2-morpholinoethyl)ethyl]-3,5-bis(2-propenyloxy)- (PCI) (CA INDEX NAME)




RU 11513-56-4 CAPLUS

CN Benzeneacetamide, 2-ethyl-6-[(4-hydroxy-2-methoxybenzoyl)-N,N-bis(2-methoxyethyl)-3,5-bis(2-propenyloxy)- (PCI) (CA INDEX NAME)




RU 11513-57-3 CAPLUS

CN Benzeneacetamide, 2-ethyl-6-[(4-hydroxy-2-methoxybenzoyl)-N,N-bis(2-methoxyethyl)-3,5-bis(2-propenyloxy)- (PCI) (CA INDEX NAME)




RU 11513-56-4 CAPLUS

CN Benzeneacetamide, 2-ethyl-6-[(4-hydroxy-2-methoxybenzoyl)-N,N-bis(2-methoxyethyl)-3,5-bis(2-propenyloxy)- (PCI) (CA INDEX NAME)




RU 11513-59-7 CAPLUS

CN Benzeneacetamide, 2-ethyl-6-[(4-dimethoxybenzoyl)-N-(2-(dimethylamino)propyl)-6-ethyl-N-(2-methoxyethyl)-3,5-bis(2-propenyloxy)- (PCI) (CA INDEX NAME)




RU 11513-50-0 CAPLUS

CN Benzeneacetamide, 2-ethyl-6-[(4-dimethoxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(2-propenyloxy)- (PCI) (CA INDEX NAME)




RU 11513-51-1 CAPLUS

CN Benzeneacetamide, 2-ethyl-6-[(4-dimethoxybenzoyl)-N-(2-methoxyethyl)-N-(2-morpholinoethyl)ethyl]-3,5-bis(2-propenyloxy)- (PCI) (CA INDEX NAME)




RU 11513-51-1 CAPLUS

CN Benzeneacetamide, N-[(2-(dimethylamino)ethyl)-2-ethyl-6-[(4-methoxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(2-propenyloxy)- (PCI) (CA INDEX NAME)




RU 11513-51-1 CAPLUS

CN Benzeneacetamide, N-[(2-(dimethylamino)ethyl)-2-ethyl-6-[(4-methoxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(2-propenyloxy)- (PCI) (CA INDEX NAME)




RU 11513-51-1 CAPLUS

CN Benzeneacetamide, N-[(2-(dimethylamino)ethyl)-2-ethyl-6-[(4-methoxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(2-propenyloxy)- (PCI) (CA INDEX NAME)




RU 11513-57-3 CAPLUS

CN Benzeneacetamide, 2-bromo-N-(2-hydroxyethyl)-6-[(4-methoxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(2-propenyloxy)- (PCI) (CA INDEX NAME)




RU 11513-59-7 CAPLUS

CN Benzeneacetamide, N-(2-hydroxyethyl)-2-iodo-6-[(4-methoxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(2-propenyloxy)- (PCI) (CA INDEX NAME)




RU 11513-57-3 CAPLUS

CN Benzeneacetamide, 2-ethyl-6-[(4-hydroxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(2-propenyloxy)- (PCI) (CA INDEX NAME)




RU 11513-57-3 CAPLUS

CN Benzeneacetamide, 2-ethyl-6-[(4-hydroxybenzoyl)-N-(2-methoxyethyl)-3,5-bis(2-propenyloxy)- (PCI) (CA INDEX NAME)




PM 15:13-15-1 CAPLUS

BN Benzeneamide, 1-[4-(2-ethoxyethyl)-2-methoxybenzoyl]-4-ethyl-N-methyl-2-methoxyethyl-3,5-bis(2-propenyl)- (SCI) (CA INDEX NAME)




PM 15:13-15-4 CAPLUS

BN Benzeneamide, 1-[4-(2-chloropropyl)-2-methoxybenzoyl]-4-ethyl-N-methyl-2-methoxyethyl-3,5-bis(2-propenyl)- (SCI) (CA INDEX NAME)



PM 15:13-15-5 CAPLUS

BN Benzeneamide, 1-[4-(2-chloropropyl)-2-methoxybenzoyl]-4-ethyl-N-methyl-2-methoxyethyl-3,5-bis(2-propenyl)- (SCI) (CA INDEX NAME)



PM 15:13-15-4 CAPLUS

41

BROAD STRUCTURE + TEXT

>> fil reg; d stat que 111; fil capl; d que nos 148; d que nos 151; a 148,151 not 144

FILE 'REGISTRY' ENTERED AT 15:08:48 ON 15 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2007 HIGHEST RN 937362-79-3
DICTIONARY FILE UPDATES: 14 JUN 2007 HIGHEST RN 937362-79-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/engen/engdoc/properties.html>

L8 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17


STEREO ATTRIBUTES: NONE
L11 625 SEA FILE=REGISTRY SSS FUL L8

100.0% PROCESSED 5028 ITERATIONS
SEARCH TIME: 00.00.01

625 ANSWERS


43

BN Benzeneamide, 1-ethyl-N,N-bis(2-methoxyethyl)-4-[3-methoxy-4-[2-(4-methyl-1-piperidinyl)-2-methoxyethyl]-5-bis(2-propenyl)- (SCI) (CA INDEX NAME)




PM 15:13-15-7 CAPLUS

BN Benzeneamide, 1-[4-(2-methoxyethyl)-2-methoxybenzoyl]-4-ethyl-N,N-bis(2-methoxyethyl)-2-methoxyethyl-3,5-bis(2-propenyl)- (SCI) (CA INDEX NAME)



PM 15:13-15-8 CAPLUS

BN Benzeneamide, 1-[4-(2-methoxyethyl)-2-methoxybenzoyl]-4-ethyl-N,N-bis(2-methoxyethyl)-2-methoxyethyl-3,5-bis(2-propenyl)- (SCI) (CA INDEX NAME)



REFERENCE COUNT:

16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

42

FILE 'CAPLUS' ENTERED AT 15:08:48 ON 15 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jun 2007 VOL 146 ISS 26

FILE LAST UPDATED: 14 Jun 2007 (20070614/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L8 STR
L11 625 SEA FILE=REGISTRY SSS FUL L8
L45 29025 SEA FILE=CAPLUS ABB=ON HEAT SHOCK/OBI OR HSP90/OBI OR HSP/OBI
L47 283 SEA FILE=CAPLUS ABB=ON L11
L48 1 SEA FILE=CAPLUS ABB=ON L47 AND L45

L8 STR
L11 625 SEA FILE=REGISTRY SSS FUL L8
L47 283 SEA FILE=CAPLUS ABB=ON L11
L49 166137 SEA FILE=CAPLUS ABB=ON ANTITUMOR AGENTS/CT
L50 484200 SEA FILE=CAPLUS ABB=ON NEOPLAS/OBI
L51 8 SEA FILE=CAPLUS ABB=ON L47 AND (L49 OR L50)

L52 7 (L48 OR L51) NOT L44

>> d ibid ed abs hitstr 1-7

L52 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 2006:845182 CAPLUS Full-text
DOCUMENT NUMBER: 145:241713
TITLE: Antitumor agents containing benzoyl compounds
INVENTOR(S): Kanda, Yutaka; Soga, Shiro; Nakashima, Takayuki; Nara, Shinji; Nakagawa, Hiroshi; Shiotsu, Yukimasa
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 61pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

44


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006082193	A1	20060824	WO 2006-09302996	20060221

W: AS, AO, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPL. INFO.: MARPAT 145:241713
OTHER SOURCE(S):
ED Entered STM: 24 Aug 2006
OI



AB Disclosed is a therapeutic agent for a tumor selected from a hematopoietic tumor and a solid tumor, comprising, as the active ingredient, a benzoyl compound represented by the general formula I or a prodrug or pharmacol. acceptable salt thereof: I wherein n is an integer of 1 to 5; R1 represents a substituted or unsubstituted lower alkoxy, a substituted or unsubstituted lower alkoxy, CONR7R8 or the like; R2 represents a substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R3 and R5 independently represent a hydrogen atom, a substituted or unsubstituted lower alkyl or the like; R4 represents a hydrogen atom, a hydroxy or a halogen; and R6 represents a hydrogen atom, a halogen, a substituted or unsubstituted lower alkyl or the like. For example, the antitumor activity of a compound I (R1 = CON(CH2CH2OH)2; n = 1; R2 = p-methoxyphenyl; R3, R4, R5 = H; R6 = Et) was in vitro tested.

IT 819810-81-6 819810-82-7 819810-85-0
819810-89-4 819810-92-9 819810-93-0
819810-94-1 819810-95-2 819810-96-3
819810-97-4 819810-98-5 819810-99-6
819811-00-2 819811-01-3 819811-02-4
819811-03-5 819811-04-6 819811-05-7
819811-06-8 819811-07-9 819811-08-0
819811-09-1 819811-10-4 819811-11-5
819811-12-6 819811-14-9 819811-15-9
819811-16-0 819811-17-1 819811-18-2
819811-19-3 819811-20-6 819811-21-7
819811-22-8 819811-23-9 819811-24-0
819811-26-2 819811-27-3 819811-28-4


45

819811-29-5	819811-33-1	819811-34-2
819811-35-3	819811-40-0	819811-43-3
819811-45-5	819811-46-6	819811-47-7
819811-48-8	819811-54-6	819811-55-7
819811-56-8	819811-57-9	819811-58-0
819811-59-1	819811-60-4	819811-61-5
819811-62-6	819811-63-7	819811-64-8
819811-65-9	819811-66-0	819811-67-1
819811-68-2	819811-69-3	819811-70-6
819811-71-7	819811-72-8	819811-73-9
819811-74-0	819811-75-1	819811-76-2
819811-77-3	819811-78-4	819811-79-5
819811-80-8	819811-81-9	819811-82-0
819811-83-1	819811-84-2	819811-85-3
819811-86-4	819811-87-5	819811-88-6
819811-89-7	819811-90-0	819811-91-1
819811-92-2	819811-93-3	819811-94-4
819811-95-5	819811-96-6	819811-97-7
819811-98-8	819811-99-9	819812-00-5
819812-01-6	819812-02-7	819812-03-8
819812-04-9	819812-05-0	819812-06-1
819812-07-2	819812-08-3	819812-09-4
819812-10-7	819812-11-8	819812-12-9
819812-13-0	819812-14-1	819812-15-2
819812-16-3	819812-17-4	819812-18-5
819812-19-6	819812-20-9	819812-21-0
819812-22-1	819812-23-2	819812-24-3
819812-25-4	819812-26-5	819812-27-6
819812-28-7	819812-29-8	819812-30-7
819812-31-8		

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor agents containing benzoyl compds.)


RN 819810-81-6 CAPLUS

CN Benzenecetic acid, 2-benzoyl-6-ethyl-3,5-dihydroxy-, methyl ester (9CI)
(CA INDEX NAME)




RN 819810-82-7 CAPLUS

CN Benzenecetic acid, 2-ethyl-3,5-dihydroxy-6-(3-methoxybenzoyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 819810-85-0 CAPLUS

CN Benzenecetic acid, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 819810-89-4 CAPLUS

CN Benzenecetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 819810-92-9 CAPLUS

CN Benzenecetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 819810-93-0 CAPLUS

CN Benzenecetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 819810-94-1 CAPLUS

CN Benzenecetic acid, 3,5-dihydroxy-2-iodo-6-(4-methoxybenzoyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 819810-95-2 CAPLUS

CN Benzenecetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-methyl-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 819810-96-3 CAPLUS

CN Piperazine, 1-(2-cyanophenyl)-4-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819810-97-4 CAPLUS


CN Benzenecetic acid, 3-hydroxy-2-(4-methoxybenzoyl)-5-(2-propenyloxy)-, methyl ester (9CI) (CA INDEX NAME)

47

46


48

methyl ester (9CI) (CA INDEX NAME)




RN 819810-98-5 CAPLUS

CN Benzeneacetic acid, 3,5-dihydroxy-2-(4-methoxybenzoyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 819810-99-6 CAPLUS

CN Benzeneacetic acid, 3,5-dihydroxy-2-(4-hydroxybenzoyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 819811-00-2 CAPLUS


CN 3-Piperidinol, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-01-3 CAPLUS


CN 3-Piperidinemethanol, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)

49




RN 819811-02-4 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 819811-03-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-04-6 CAPLUS


CN 3-Pyrrolidinol, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-05-7 CAPLUS


CN Benzeneacetamide, N-(2,3-dihydroxypropyl)-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-methyl- (9CI) (CA INDEX NAME)

50




RN 819811-06-8 CAPLUS

CN Benzeneacetic acid, 5-hydroxy-3-methoxy-2-(4-methoxybenzoyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 819811-07-9 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 819811-08-0 CAPLUS


CN Benzeneacetic acid, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-, methyl ester (9CI) (CA INDEX NAME)



RN 819811-09-3 CAPLUS


CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-

phenyl- (9CI) (CA INDEX NAME)




RN 819811-10-4 CAPLUS

CN 4-Piperidinol, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 819811-11-5 CAPLUS

CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-(2-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 819811-12-6 CAPLUS


CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(3-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-14-8 CAPLUS

CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)


52




RN 819811-15-9 CAPLUS
CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-16-0 CAPLUS
CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 819811-17-1 CAPLUS
CN Isoquinoline, 2-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 819811-18-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-N-(2-furanylmethyl)-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-methyl- (9CI) (CA INDEX NAME)

53


RN 819811-19-3 CAPLUS
CN 1-Piperazineethanol, 4-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 819811-23-9 CAPLUS
CN Morpholine, 4-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 819811-24-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 819811-26-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)




55




RN 819811-19-3 CAPLUS
CN 1-Piperazineethanol, 4-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 819811-20-6 CAPLUS
CN Piperazine, 1-[[2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxyphenyl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 819811-21-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 819811-22-8 CAPLUS

54


RN 819811-27-3 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 819811-28-4 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-29-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-6-(4-fluorobenzoyl)-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-33-1 CAPLUS
CN Isoquinoline, 2-[[2-ethyl-6-(4-fluorobenzoyl)-3,5-dihydroxyphenyl]acetyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)




56


RN 819811-34-2 CAPLUS
CN Piperazine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-hydroxybenzoyl)phenyl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 819811-35-3 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-40-0 CAPLUS
CN 4-Piperidinemethanol, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 819811-43-3 CAPLUS
CN Piperazinone, 1-(3-chlorophenyl)-4-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]- (9CI) (CA INDEX NAME)




57


RN 819811-54-6 CAPLUS
CN Piperazinone, 4-[[2-benzoyl-6-ethyl-3,5-dihydroxyphenyl]acetyl]-1-(2-cyanophenyl)- (9CI) (CA INDEX NAME)




RN 819811-55-7 CAPLUS
CN Benzeneacetamide, 2-benzoyl-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-56-8 CAPLUS
CN Benzeneacetamide, 2-benzoyl-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-57-9 CAPLUS
CN 4-Piperidinemethanol, 1-[[2-benzoyl-6-ethyl-3,5-dihydroxyphenyl]acetyl]- (9CI) (CA INDEX NAME)




59


RN 819811-45-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-6-(4-fluorobenzoyl)-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-46-6 CAPLUS
CN Piperidine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 819811-47-7 CAPLUS
CN Piperazinone, 4-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 819811-48-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-N-(2-furanylmethyl)-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)




58


RN 819811-58-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(3-hydroxybenzoyl)-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-59-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-hydroxybenzoyl)-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-60-4 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-hydroxybenzoyl)-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-61-5 CAPLUS
CN Piperazinone, 4-[[2-ethyl-6-(4-fluorobenzoyl)-3,5-dihydroxyphenyl]acetyl]-1-phenyl- (9CI) (CA INDEX NAME)




60




RN 819811-62-6 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(3-hydroxy-4-methoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 819811-63-7 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(3-hydroxy-4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-64-8 CAPLUS


CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(3-fluoro-4-methoxybenzoyl)-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



61


RN 819811-65-9 CAPLUS

CN Benzeneacetamide, 2-ethyl-6-(3-fluoro-4-methoxybenzoyl)-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-66-0 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(4-(trifluoromethoxy)benzoyl)- (9CI) (CA INDEX NAME)




RN 819811-67-1 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-(trifluoromethoxy)benzoyl)- (9CI) (CA INDEX NAME)



RN 819811-68-2 CAPLUS


CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(3-hydroxy-4-methoxybenzoyl)-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)



62


RN 819811-69-3 CAPLUS

CN Benzeneacetamide, 2-[4-(difluoromethoxy)benzoyl]-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-70-6 CAPLUS

CN Benzeneacetamide, 2-[4-(difluoromethoxy)benzoyl]-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-71-7 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(3-hydroxy-4-methylbenzoyl)- (9CI) (CA INDEX NAME)



RN 819811-72-8 CAPLUS


CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(3-hydroxy-4-methylbenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



63


RN 819811-73-9 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(3-hydroxypropyl)-6-[4-(trifluoromethoxy)benzoyl]- (9CI) (CA INDEX NAME)




RN 819811-74-0 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(methylthio)benzoyl]- (9CI) (CA INDEX NAME)




RN 819811-75-1 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-[4-(methylsulfonyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-76-2 CAPLUS


CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(methylsulfonyl)benzoyl]- (9CI) (CA INDEX NAME)




64

RN 819811-77-3 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 819811-78-4 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN 819811-79-5 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-N-(2-furanylmethyl)-3,5-dihydroxy-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-80-6 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(3-hydroxypropyl)-6-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 819811-81-9 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-[3-(2-hydroxyethoxy)-4-methoxybenzoyl]-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-82-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-methoxy-3-(2-methoxyethoxy)benzoyl)- (9CI) (CA INDEX NAME)



RN 819811-83-1 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-methoxy-3-[2-(4-morpholinyl)ethoxy]benzoyl)- (9CI) (CA INDEX NAME)




RN 819811-84-2 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-hydroxy-3-


65

66


methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-85-3 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-hydroxy-3-methoxybenzoyl)-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819811-86-4 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[4-(methylsulfonyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 819811-87-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-(2-hydroxyethoxy)-3-methoxybenzoyl)-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-88-6 CAPLUS


CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(3-methoxy-4-(2-methoxyethoxy)benzoyl)- (9CI) (CA INDEX NAME)




RN 819811-89-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[3-methoxy-4-[2-(4-morpholinyl)ethoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 819811-90-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 819811-91-1 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-N-[2-(dimethylamino)ethyl]-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




67

68


RN 819811-92-2 CAPLUS
CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-93-3 CAPLUS
CN Benzeneacetamide, N-[2-(diethylamino)ethyl]-2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-94-4 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 819811-95-5 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 819811-96-6 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(3-hydroxypropyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-97-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 819811-98-8 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(3-hydroxypropyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819811-99-9 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 819812-00-5 CAPLUS
CN Benzeneacetamide, 2-(4-ethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-01-6 CAPLUS
CN Benzeneacetamide, 2-(4-ethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-02-7 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-(4-(1-methylethoxy)benzoyl)- (9CI) (CA INDEX NAME)




RN 819812-03-8 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-(4-(1-methylethoxy)benzoyl)- (9CI) (CA INDEX NAME)




RN 819812-04-9 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-(3-methoxy-4-[2-(4-morpholinyl)ethoxy]benzoyl)- (9CI) (CA INDEX NAME)




RN 819812-05-0 CAPLUS
CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-6-(4-(2-hydroxyethoxy)-3-methoxybenzoyl)-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 819812-06-1 CAPLUS
CN Benzeneacetamide, 2-(3,4-dimethoxybenzoyl)-N-[3-(dimethylamino)propyl]-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-07-2 CAPLUS
CN Benzeneacetamide, N-[3-(dimethylamino)propyl]-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-08-3 CAPLUS

CN Benzeneacetamide, N-[2-((diethylamino)ethyl)-2-(3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)




RN 819812-09-4 CAPLUS

CN Benzeneacetamide, N-[2-((diethylamino)ethyl)-2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)]- (9CI) (CA INDEX NAME)




RN 819812-10-7 CAPLUS

CN Piperidine, 1-[[2-((3,4-dimethoxybenzoyl)-6-ethyl-3,5-dihydroxyphenyl)acetyl]-4-(4-morpholinyl)]- (9CI) (CA INDEX NAME)




RN 819812-11-8 CAPLUS

CN Piperidine, 1-[[2-ethyl-3,5-dihydroxy-6-(4-methoxybenzoyl)phenyl]acetyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 819812-12-9 CAPLUS

CN Benzeneacetamide, 2-(4-ethoxybenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 819812-13-0 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-methoxyethyl)-6-[4-(1-methylethoxy)benzoyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 819812-14-1 CAPLUS

CN Benzeneacetamide, 2-bromo-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-15-2 CAPLUS

CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-6-(4-methoxybenzoyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-16-3 CAPLUS

CN Benzeneacetamide, N-[2-((dimethylamino)ethyl)-2-(3,4-bis(2-methoxyethoxy)benzoyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)]- (9CI) (CA INDEX NAME)




RN 819812-17-4 CAPLUS

CN Benzeneacetamide, N-[2-((dimethylamino)ethyl)-2-(3,4-bis(2-methoxyethoxy)benzoyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)]- (9CI) (CA INDEX NAME)



RN 819812-18-5 CAPLUS


CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-(2-(4-morpholinyl)ethoxy)benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 819812-19-6 CAPLUS

CN Benzeneacetamide, N-[2-((dimethylamino)ethyl)-2-(3,4-bis(2-methoxyethoxy)benzoyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)]- (9CI) (CA INDEX NAME)




RN 819812-20-9 CAPLUS

CN Benzeneacetamide, N-[2-((dimethylamino)ethyl)-2-(3,4-bis(2-methoxyethoxy)benzoyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)]- (9CI) (CA INDEX NAME)



RN 819812-21-0 CAPLUS


CN Benzeneacetamide, N-[2-((dimethylamino)ethyl)-2-(3,4-bis(2-methoxyethoxy)benzoyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)]- (9CI) (CA INDEX NAME)




● HCl

RN 819812-22-1 CAPLUS


CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)-6-[4-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 819812-23-2 CAPLUS
 CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-6-[4-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 819812-24-3 CAPLUS
 CN Benzeneacetamide, 2-(3,4-difluorobenzoyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-25-4 CAPLUS
 CN Benzeneacetamide, 2-(3,4-difluorobenzoyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 819812-26-5 CAPLUS
 CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-(2-(1-piperidinyl)ethoxy)benzoyl]- (9CI) (CA INDEX NAME)



77



RN 819812-37-8 CAPLUS
 CN Benzeneacetamide, 2-(1,3-benzodioxol-5-ylcarbonyl)-6-ethyl-3,5-dihydroxy-N-(2-hydroxyethyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS2 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:451630 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 141:23557
 TITLES: Preparation of (R)-2,3-benzodiazepines for the treatment of neutropenia.

INVENTOR(S): Harris, Herbert M.; Kucharik, Robert P.

PATENT ASSIGNEE(S): Vela Pharmaceuticals, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 20 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004106601	A1	20040603	US 2002-309527	20021203
US 7022700	B2	20060404		
US 2004138210	A1	20040715	US 2003-728286	20031202
WO 2004050615	A2	20040617	WO 2003-US38634	20031203
WO 2004050615	A3	20040805		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BM, BH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TO


AU 2003102682 A1 20040623 AU 2003-302682 20031203
 PRIORITY APPL. INFO.: US 2002-309527 20021203

79


RN 819812-27-6 CAPLUS
 CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-[2-(4-morpholinyl)-1-piperidinyl]ethoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 819812-28-7 CAPLUS
 CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-[3-(4-morpholinyl)propoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 819812-29-8 CAPLUS
 CN Benzeneacetamide, 2-ethyl-3,5-dihydroxy-N,N-bis(2-methoxyethyl)-6-[3-methoxy-4-[2-(4-methyl-1-piperazinyl)-2-oxoethoxy]benzoyl]- (9CI) (CA INDEX NAME)



RN 819812-36-7 CAPLUS
 CN Benzeneacetamide, 2-(1,3-benzodioxol-5-ylcarbonyl)-6-ethyl-3,5-dihydroxy-N,N-bis(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

78

OTHER SOURCE(S): MARPAT 141:23557
 WD Entered STN: 04 Jun 2004
 OI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = alkylhydrocarbyl, heteroalkyl; R2 = H, hydrocarbyl, wherein R1 and R2 may combine to form a carbocyclic or heterocyclic 5- or 6-membered ring; X = (R3)n; R3 = O-alkyl, OH, O-acyl, etc.; n = 1-3; R4, R5 = O-alkyl, OH, O-acyl, etc., wherein R4 and R5 may combine to form a 5-, 6-, 7-membered heterocyclic ring] and their pharmaceutically acceptable salts were prepared. For example, condensation-cyclization of diketone II, e.g., prepared from 3-methoxy-4-hydroxybenzoic acid in 7-steps, and hydrazine hydrate afforded racemic benzodiazepine III. In a 16-day study of neutrophil production in rats, one example of compound I, e.g., R-tofisopam, significantly increased neutrophil levels in a dose-dependent manner. Compds. I are claimed useful for increasing the production of neutrophils.


IT 518056-34-1P, 3-[4,5-Dimethoxy-2-[[4-methoxy-3-(phenylmethoxy)phenyl]carbonyl]phenyl]pentan-2-one 518056-36-3P, 3-[2-[(1,3-Hydroxy-4-methoxyphenyl)carbonyl]-4,5-dimethoxyphenyl]pentan-2-one 518056-39-6P, 3-[4-Benzyloxy-5-methoxy-2-[(1,3,4-dimethoxyphenyl)carbonyl]phenyl]pentan-2-one 518056-57-7P, 3-[2-[(1,3,4-Dimethoxyphenyl)carbonyl]-4-hydroxy-5-methoxyphenyl]pentan-2-one

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Preparation of benzodiazepines for the treatment of neutropenia.)


RN 518056-34-1 CAPLUS

CN 2-Pentanone, 3-[4,5-dimethoxy-2-[4-methoxy-3-(phenylmethoxy)benzoyl]phenyl]- (CA INDEX NAME)




RN 518056-36-3 CAPLUS

CN 2-Pentanone, 3-[2-(3-hydroxy-4-methoxybenzoyl)-4,5-dimethoxyphenyl]- (CA INDEX NAME)




80

RN 618056-39-6 CAPLUS
CN 2-Pentanone, 3-[2-(3,4-dimethoxybenzoyl)-5-methoxy-4-(phenylmethoxy)phenyl]- (CA INDEX NAME)




RN 697754-57-7 CAPLUS
CN 2-Pentanone, 3-[2-(3,4-dimethoxybenzoyl)-4-hydroxy-5-methoxyphenyl]- (CA INDEX NAME)




L52 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:326400 CAPLUS [Full-text](#)
DOCUMENT NUMBER: 139:374215
TITLE: Synthesis and cytotoxic activity of 1,3-benzodioxole derivatives. Note 11
AUTHOR(S): Micale, Nicola; Zappala, Maria; Grasso, Silvana
CORPORATE SOURCE: Dipartimento Farmaco-Chimico, Universita di Messina, Messina, 98168, Italy
SOURCE: Farmaco (2003), 58(5), 351-355
CODEN: FRMCB8; ISSN: 0014-827X
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:374215
RD Entered STN: 29 Apr 2003
AB A series of 1,3-benzodioxoles (2-12) were synthesized and evaluated for their in vitro ability to inhibit the growth of thraa human tumor cell lines. No cytotoxic effects were noticed with any of the test compds. at a concentration of 10-4 M.
IT 132813-95-7P 197369-12-3P 501328-34-3P
623944-58-1P 623944-59-2P 623944-65-0P
623944-66-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and cytotoxic activity of 1,3-benzodioxole derive.)
RN 132813-95-7 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-benzoyl-, methyl ester (CA INDEX NAME)


81




RN 623944-65-0 CAPLUS
CN 1,3-Benzodioxole-5-acetamide, N-methyl-6-(4-nitrobenzoyl)- (9CI) (CA INDEX NAME)



RN 623944-66-1 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-nitrobenzoyl)-, hydrazide (9CI) (CA INDEX NAME)




IT 197369-14-5P 209851-94-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and cytotoxic activity of 1,3-benzodioxole derive.)
RN 197369-14-5 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-nitrobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 209851-94-5 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-nitrobenzoyl)-, ethyl ester (9CI) (CA INDEX NAME)


83




RN 197369-12-3 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-fluorobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 501328-34-3 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-aminobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 623944-58-1 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-chlorobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 623944-59-2 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-aminobenzoyl)-, ethyl ester (9CI) (CA INDEX NAME)

82



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L52 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:967951 CAPLUS [Full-text](#)
DOCUMENT NUMBER: 138:237975
TITLE: Synthesis and antitumor activity of 1,3-benzodioxole derivatives
AUTHOR(S): Micale, Nicola; Zappala, Maria; Grasso, Silvana
CORPORATE SOURCE: Dipartimento farmaco-chimico, universita di Messina, Messina, 98168, Italy
SOURCE: Farmaco (2002), 57(10), 853-859
CODEN: FRMCB8; ISSN: 0014-827X
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:237975
RD Entered STN: 01 Dec 2002
OI




AB A series of 1,3-benzodioxoles was synthesized and evaluated for their in vitro antitumor activity against human tumor cell lines. Some derive exhibited tumor growth inhibition activity. In particular, 6-(4-aminobenzoyl)-1,3-benzodioxole-5-acetic acid Me ester (I), the most active compound of the series, possesses a significant growth inhibitory activity on 52 cell lines at concns. ranging from 10-7 to 10-5 M.

IT 197369-14-5P 433716-67-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of a series of 1,3-benzodioxoles from 1,3-benzodioxole-5-acetonitrile and evaluation of their antitumor activity)
RN 197369-14-5 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-nitrobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)


84




RN 433716-67-7 CAPLUS
CN 2-Propanone, 1-[6-(4-nitrobenzoyl)-1,3-benzodioxol-5-yl]- (9CI) (CA INDEX NAME)



IT 501328-34-3P 501328-36-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(Preparation of a series of 1,3-benzodioxoles from 1,3-benzodioxole-5-acetonitrile and evaluation of their antitumor activity)
RN 501328-34-3 CAPLUS
CN 1,3-Benzodioxole-5-acetic acid, 6-(4-aminobenzoyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 501328-36-5 CAPLUS
CN 2-Propanone, 1-[6-(4-aminobenzoyl)-1,3-benzodioxol-5-yl]- (9CI) (CA INDEX NAME)




85

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Preparation of a (naphthyridinylethoxy)dibenzocyclohepteneacetic acid as a vitronectin receptor antagonist)
RN 77605-57-3 CAPLUS
CN Benzenecetic acid, 2-benzoyl-4-methoxy- (9CI) (CA INDEX NAME)



RN 210465-72-6 CAPLUS
CN Butanedioic acid, [2-(3-methoxybenzoyl)phenyl]-, 4-ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:659355 CAPLUS Full-text
DOCUMENT NUMBER: 131:286273
TITLE: Preparation of hydroxyphenoxypropyl naphthylethylamines, methoxyphenylethylaminephenoxypropanols, and related compounds as calcilytics.
INVENTOR(S): Bhatnagar, Pradip Kumar; Burgess, Joelle Lorraine; Callahan, James Francis; Calvo, Raul Rolando; Del Mar, Eric G.; Lego, Maria Amparo; Nguyen, Thomas The
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA; NPS Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951569	A1	19991014	WO 1999-US7722	19990408
W: AS, AL, AU, BA, BS, BR, CA, CN, CZ, DE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MQ, MX, MN, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:401648 CAPLUS Full-text
DOCUMENT NUMBER: 131:43507
TITLE: Preparation of a (naphthyridinylethoxy)dibenzocyclohepteneacetic acid as a vitronectin receptor antagonist
INVENTOR(S): Miller, William H.; Manley, Peter J.
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033838	A1	20000615	WO 1999-US28662	19991203
W: AS, AL, AU, BA, BS, BR, CA, CN, CZ, DE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RM: OH, OM, OS, LS, MW, SD, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CO, CI, CM, GA, GM, GW, MD, MR, NE, NG, TD, TO				
TM 482673	B	20020411	TM 1999-88120752	19991129
CA 2353415	A1	20000615	CA 1999-2353415	19991203
EP 1146874	A1	20011024	EP 1999-960647	19991203
EP 1146874	B1	20040922		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9915879	A	20020213	BR 1999-15879	19991203
TR 200101654	T2	20020321	TR 2001-200101654	19991203
HU 200104804	A2	20020529	HU 2001-4804	19991203
AU 754408	B2	20021114	AU 2000-17502	19991203
JP 2003523931	T	20030812	JP 2000-586330	19991203
NZ 511876	A	20040227	NZ 1999-511876	19991203
AT 277043	T	20041015	AT 1999-960647	19991203
PT 1146874	T	20050228	PT 1999-960647	19991203
ES 2229798	T3	20050416	ES 1999-960647	19991203
AP 1534	A	20060228	AP 2001-2156	19991203
W: OH, OM, OS, LS, MW, SD, SZ, TZ, UG, ZW				
IN 2001000593	A	20050304	IN 2001-M0593	20010525
ZA 2001004398	A	20020529	ZA 2001-4398	20010529
NO 2001002732	A	20010801	NO 2001-2732	20010601
NO 318895	B1	20050518		
US 6495560	B1	20021217	US 2001-857316	20010712
HK 1042037	A1	20050729	HK 2002-101522	20020227
PRIORITY APPLN. INFO.:			US 1998-110903P	P 19991204
			WO 1999-US28662	W 19991203

ED Entered STN: 16 Jun 2000
Bt (S)-10,11-dihydro-3-hydroxy-5H-dibenzo[a,d]cycloheptene-10-acetate was esterified by 2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethanol (preparation each given) and the product saponified to give (S)-10,11-dihydro-3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid (I). Data for biol. activity of I were given.
IT 77605-57-3P 210465-72-6P

86

RM: OH, OM, OS, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CO, CI, CM, GA, GM, GW, MD, MR, NE, NG, TD, TO
CA 2327279 A1 19991014 CA 1999-2327279 19990408
AU 9914819 A 19991025 AU 1999-34819 19990408
AU 752389 B2 20020919
TR 200002896 T2 20010122 TR 2000-200002896 19990408
EP 1070048 A1 20010124 EP 1999-916516 19990408
EP 1070048 B1 20050831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO
HU 200101346 A2 20010828 HU 2001-1346 19990408
BR 9909406 A 20011106 BR 1999-9406 19990408
ZA 200005369 A 20011218 ZA 2000-5369 19990408
JP 2002510671 T 20020409 JP 2000-542291 19990408
NZ 507288 A 20030530 NZ 1999-507288 19990408
AP 1271 A 20040421 AP 2000-1931 19990408
W: OH, OM, OS, LS, MW, SD, SZ, UG, ZW
AT 303358 T 20050915 AT 1999-916516 19990408
ES 2247795 T3 20060301 ES 1999-916516 19990408
NO 200005006 A 20001004 NO 2000-5006 20010404
US 6395919 B1 20000518 US 2000-647793 20001005
IN 20000000483 A 20050318 IN 2000-M0483 20001009
BG 104916 A 20010629 BG 2000-104916 20001107
HK 1034243 A1 20060421 HK 2001-104722 20010709
PRIORITY APPLN. INFO.:

US 1998-81093P P 19980408
WO 1999-US7722 W 19990408
OTHER SOURCE(S): MARPAT 131:286273
ED Entered STN: 15 Oct 1999
GI



AB Title compds. [I: Y1 = bond, (O- or alkyl-substituted) alkylene, alkenylene; Y2 = (alkyl- or haloalkyl-substituted) methylene; Y3 = bond, O, S, imino, alkyleneoxy, alkyleneimino, alkyleneimino; R3, R4 = Me, Et; R3R4C = cyclopropyl; R5 = (fused) (substituted) aryl; G = bond, CHR6, CR6; R6 = H, OH, O; R7 = H, OH, alkoxy; R8 = H, alkyl; R7R8 = O; A, B = bond, CH2, NH, O, S, CO; A = CH2CH, C.tpbond.C; X1, X5 = H, halo, cyano, NO2, alkyl, cycloalkyl, arylmethyl, heteroaryl, heteroarylalkyl; X2-X4 = H, halo, alkoxy, aryloxy, heteroaryloxy, arylmethyl, heteroaryl, heteroarylalkyl, heteroarylcarbonyl, etc.; with proviso], were prepared as calcium receptor antagonists for treatment of abnormal bone or mineral homeostasis (no data). Thus, (R)-4-[2-(RS)-(methoxycarbonyl)ethyl]phenoxycyclopropanol (preparation given), 4-methoxyphenyl-1,1-dimethyl-2-(4-methoxyphenyl)ethylamine, and 2-NH2 were refluxed 24 h in EtOH to give (R)-1-[1,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-(4-[2-phenyl-2-(RS)-methoxycarbonyl]ethyl)phenoxycyclopropan-2-ol hydrochloride.
IT 77605-57-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(Preparation of hydroxyphenoxypropyl naphthylethylamines, methoxyphenylethylaminephenoxypropanols, and related compds. as calcilytics)


87

88

10/561415

STIC

RN 77605-57-3 CAPLUS
 CN Benzeneacetic acid, 2-benzoyl-4-methoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS2 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1996:417842 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 125:76353
 TITLE: Inhibitors of farnesyl-protein transferase
 INVENTOR(S): Stokker, Gerald E.; Graham, Samuel L.
 PATENT ASSIGNER(S): Merck and Co., Inc., USA; Stokker, Gerald, E.; Graham, Samuel, L.
 SOURCE: PCT Int. Appl., 127 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9610011	A1	19960404	WO 1995-US12321	19950925
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, DE, FI, GE, HU, IS, JP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ				
RW: KE, MM, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5521456	A	19960604	US 1994-315046	19940929
CA 2201351	A1	19960404	CA 1995-2701351	19950925
AU 9536426	A	19960419	AU 1995-36426	19950925
AU 689651	B2	19980402		
EP 787123	A1	19970806	EP 1995-933957	19950925
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 10506898	T	19980707	JP 1996-511981	19950925
PRIORITY APPLN. INFO.:				
			US 1994-315046	A2 19940929
			WO 1995-US12321	W 19950925

ED Entered STN: 17 Jul 1996
 AB The present invention comprises analogs of the CAAX motif of the protein Ras that is modified by farnesylation in vivo. These CAAX analogs inhibit the farnesylation of Ras. Furthermore, these CAAX analogs differ from those previously described as inhibitors of Ras farnesyl transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid auto-oxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compns. containing these farnesyl transferase inhibitors and methods for their production

89

10/561415

STIC

NARROWER STRUCTURE SEARCH

=> fil reg; d stat que 142; fil capl
 FILE 'REGISTRY' ENTERED AT 15:09:42 ON 15 JUN 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2007 HIGHEST RN 937362-79-3
 DICTIONARY FILE UPDATES: 14 JUN 2007 HIGHEST RN 937362-79-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

L8 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
 L11 625 SEA FILE-REGISTRY SSS FUL L8
 L35 STR


91

10/561415

STIC


IT 178449-02-0P 178449-18-8P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRSP (Preparation); USES (Uses)
 (preparation of analogs of CAAX motif of protein Ras for inhibiting Ras farnesyl-transferase and for treating cancer)
 RN 178449-02-0 CAPLUS
 CN L-Methionine, N-[N-[2-[[[2-benzoylphenyl]acetyl]amino]-4-methylpentyl]-N-(1-naphthalenylmethyl)glycyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 178449-18-8 CAPLUS
 CN L-Methionine, N-[N-[2-[[[2-benzoylphenyl]acetyl]amino]-4-methylpentyl]-N-(1-naphthalenylmethyl)glycyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



90

10/561415

STIC




O 019 O 020

VPA 19-9/10/11/12 U
 VPA 20-1/2/4/5/6 U
 NODE ATTRIBUTES:
 NSPEC IS RC AT 16
 DEFAULT MLEVEL IS ATOM
 DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
 L38 STR




O 018 O 019

VPA 18-9/10/11/12 U
 VPA 19-9/10/11/12 U
 NODE ATTRIBUTES:
 NSPEC IS RC AT 16
 DEFAULT MLEVEL IS ATOM
 DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
 L39 STR



O 020 O 021

92

VPA 20-1/2/4/5/6 U
VPA 21-1/2/4/5/6 U
NODE ATTRIBUTES:
NSPEC 18 RC
DEFAULT MLEVEL IS ATOM
DEFAULT ELEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L42 151 SEA FILE=REGISTRY SUB=L11 SSS FUL (L35 OR L38 OR L39)

100.0% PROCESSED 193 ITRATIONS 151 ANSWERS
SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 15:09:43 ON 15 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jun 2007 VOL 146 ISS 26
FILE LAST UPDATED: 14 Jun 2007 (20070614/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>
'OBJ' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

--> d que nos 143; s 143 not 144,152

L8 STR
L11 625 SEA FILE=REGISTRY SSS FUL L8
L35 STR
L38 STR
L39 STR
L42 151 SEA FILE=REGISTRY SUB=L11 SSS FUL (L35 OR L38 OR L39)
L43 5 SEA FILE=CAPLUS ABB=ON L42


L53 3 L43 NOT (L44 OR L52)

--> d ibib ed abe hitetr 1-3; fil hom

93


L53 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 2005:408217 CAPLUS Full-text
Correction of: 2005:155220
DOCUMENT NUMBER: 143:266757
Correction of: 142:197771
TITLES: Product class 5: isoquinolines
AUTHOR(S): Alvarez, M.; Joule, J. A.
CORPORATE SOURCE: Germany
SOURCE: Science of Synthesis (2005), 15, 661-838
CODEN: SSCYJ9
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
ED Entered STN: 13 May 2005
AB A review primarily covering methods of preparation of isoquinolines via cyclization, ring transformations or substituent modification. Isoquinoline 2-oxides and isoquinolinium salts are also included.
IT 180072-41-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of isoquinolines and analogs via cyclization, ring transformations or substituent modifications)
RN 180072-41-7 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-hydroxy-1-phenylethyl]-4,5-dimethoxy-2-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L53 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 1996:376527 CAPLUS Full-text
DOCUMENT NUMBER: 125:167761
TITLES: Asymmetric synthesis. XII. Totally stereoselective synthesis of 1,3-disubstituted tetrahydroisoquinolines via the CN(R,S) method
AUTHOR(S): Gosmann, Grace; Guillaume, Dominique; Russon, Henri-Philippe
CORPORATE SOURCE: Lab. Chimie Therapeutique associe CNRS, Univ. R. Descartes, Paris, 75270, Fr.
SOURCE: Tetrahedron Letters (1996), 37(25), 4369-4372
CODEN: TETLEA; ISSN: 0040-4039
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 125:167761
ED Entered STN: 28 Jun 1996
OI

94




AB Optically active cis- or trans- 1,3-disubstituted tetrahydroisoquinolines 3-R- or 3S-I (R = Me, CH2Ph) can be prepared selectively from the same oxazolidine II. This latter is easily obtained from keto-acid III and (R)-(-)-phenylglycinol.

IT 180072-41-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereoselective preparation of isoquinolines)

RN 180072-41-7 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-hydroxy-1-phenylethyl]-4,5-dimethoxy-2-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L53 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 1974:108242 CAPLUS Full-text
DOCUMENT NUMBER: 80:108242
TITLES: Tetracycline studies. IV. Novel cyclizations through benzophenone carbanions, including a new synthesis of anthraquinones
AUTHOR(S): Hassell, Cedric H.; Morgan, Barry A.
CORPORATE SOURCE: Dep. Chem., Univ. Coll. Swansea, Swansea, UK
SOURCE: Journal of the Chemical Society, Perkin Transactions

95

1: Organic and Bio-Organic Chemistry (1972-1999)
(1973), (23), 2853-61
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 12 May 1984
OI For diagram(s), see printed CA issue.
AB 2,3,5-Me(MeO)2C6H2CH2CN with 2,4,6,3-(MeO)3C6HCO2H in (F3CCO)2O gave 71% benzophenone (I) which with NaOMe in DMF gave 95% anthrol (II). II with H2O2 and NaOH gave 96% 1,3,6,8-tetramethoxy-2-(methoxycarbonyl)-5-methylanthraquinone which gave the 6-methylpretetramid analog (III) in 3 steps. Other anthraquinones including emodin and physcion were prepared similarly.
IT 52344-90-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 52344-90-8 CAPLUS
CN Benzeneacetamide, N,2-bis(2,6-dimethoxybenzoyl)-3,5-dimethoxy- (9CI) (CA INDEX NAME)




FILE 'HOME' ENTERED AT 15:10:23 ON 15 JUN 2007

96

SEARCH HISTORY

== d stat quo 142; d his nobile
L8 STR




NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT RLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

L11 625 SEA FILE-REGISTRY SSS FUL L8
L35 STR



0019 0020

VPA 19-9/10/11/12 U


VPA 20-1/2/4/5/6 U

MODE ATTRIBUTES:
NSPEC IS RC AT 16
DEFAULT MLEVEL IS ATOM
DEFAULT RLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

L38 STR



0018 0019

VPA 18-9/10/11/12 U


VPA 19-9/10/11/12 U

MODE ATTRIBUTES:
NSPEC IS RC AT 16
DEFAULT MLEVEL IS ATOM
DEFAULT RLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

L39 STR



0020 0021

VPA 20-1/2/4/5/6 U

VPA 21-1/2/4/5/6 U

MODE ATTRIBUTES:
NSPEC IS RC AT 16
DEFAULT MLEVEL IS ATOM
DEFAULT RLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

L42 151 SEA FILE-REGISTRY SUB=L11 SSS FUL (L35 OR L38 OR L39)

100.0% PROCESSED 193 ITERATIONS 151 ANSWERS
SEARCH TIME: 00.00.01

(FILE 'HOME' ENTERED AT 14:40:53 ON 15 JUN 2007)

FILE 'REGISTRY' ENTERED AT 14:41:33 ON 15 JUN 2007

97

98

L1 STR

L2 5 SEA SSS SAM L1

FILE 'ZCAPLUS' ENTERED AT 14:44:51 ON 15 JUN 2007

L3 2 SEA ABB-ON L2
D SCAN T1

FILE 'REGISTRY' ENTERED AT 14:45:22 ON 15 JUN 2007

L4 STR L1

L5 5 SEA SSS SAM L4

L6 STR L4

L7 11 SEA SSS SAM L6

L8 STR L6

L9 33 SEA SSS SAM L8

L10 5025 SEA SSS FUL L8 EXTEND

L11 625 SEA SSS FUL L8
SAVE TEMP L11 HAV415FULL/A

FILE 'ZCAPLUS' ENTERED AT 14:47:02 ON 15 JUN 2007

L12 283 SEA ABB-ON L11

FILE 'REGISTRY' ENTERED AT 14:48:19 ON 15 JUN 2007

L13 STR L8

L14 STR L4

L15 STR L4

L16 22 SEA SUB=L11 SSS SAM (L13 OR L14 OR L15)

FILE 'STNGUIDE' ENTERED AT 14:52:39 ON 15 JUN 2007

FILE 'ZCAPLUS' ENTERED AT 14:52:47 ON 15 JUN 2007

L17 23 SEA ABB-ON L16

FILE 'REGISTRY' ENTERED AT 14:53:43 ON 15 JUN 2007

L18 STR L4

L19 5 SEA SUB=L11 SSS SAM L18

L20 5 SEA ABB-ON L5 AND L19

FILE 'CAPLUS' ENTERED AT 14:54:46 ON 15 JUN 2007

L21 1 SEA ABB-ON US2005-561415/APPS
D SCAN
SEL RN

FILE 'REGISTRY' ENTERED AT 14:55:14 ON 15 JUN 2007

L22 412 SEA ABB-ON (100-09-4/BI OR 100-52-7/BI OR 103-76-4/BI OR
10345-98-7/BI OR 106-95-6/BI OR 109-01-3/BI OR 109-70-6/BI OR
109-83-1/BI OR 109-85-3/BI OR 109384-19-2/BI OR 110-87-2/BI OR
110-91-8/BI OR 111-42-2/BI OR 111-95-5/BI OR 111373-03-6/BI OR
123-11-5/BI OR 126495-72-5/BI OR 13205-46-4/BI OR 13205-48-6/BI
OR 13889-98-0/BI OR 141699-59-4/BI OR 16015-71-7/BI OR
1694-92-4/BI OR 17739-45-6/BI OR 18228-11-4/BI OR 183322-16-9/B
I OR 183500-84-9/BI OR 189205-49-0/BI OR 19344-29-7/BI OR
20173-04-0/BI OR 208245-69-6/BI OR 214360-76-6/BI OR 2328-12-3/
BI OR 290328-55-1/BI OR 3240-94-6/BI OR 329-15-7/BI OR
330-12-1/BI OR 331-64-6/BI OR 34328-61-5/BI OR 34750-64-6/BI
OR 34841-06-0/BI OR 3485-05-0/BI OR 351-54-2/BI OR 3647-69-6/BI
OR 3731-52-0/BI OR 38256-93-8/BI OR 39216-84-7/BI OR 3943-89-3
/BI OR 39546-32-2/BI OR 40137-22-2/BI OR 40499-83-0/BI OR
40807-61-2/BI OR 4138-26-5/BI OR 4439-22-9/BI OR 456-22-4/BI
OR 4606-65-9/BI OR 4724-10-1/BI OR 4753-75-7/BI OR 4837-20-1/BI

99

OR 488-93-7/BI OR 51254-17-2/BI OR 527-72-0/BI OR 5332-73-0/BI
OR 53617-35-9/BI OR 5407-04-5/BI OR 54093-33-3/BI OR 555-16-8/
BI OR 586-38-9/BI OR 59817-32-2/BI OR 621-51-2/BI OR 622-26-4/B
I OR 627-30-5/BI OR 645-08-9/BI OR 6457-49-4/BI OR 6482-24-2/BI
OR 65-85-0/BI OR 6859-99-0/BI OR 68832-13-3/BI OR 7663-77-6/BI
OR 76903-88-3/BI OR 819810-73-6/BI OR 819810-75-8/BI OR
819810-77-0/BI OR 819810-79-2/BI OR 819810-81-6/BI OR 819810-83
-7/BI OR 819810-83-8/BI OR 819810-85-0/BI OR 819810-87-2/BI OR
819810-89-4/BI OR 819810-90-7/BI OR 819810-91-8/BI OR 819810-92
-9/BI OR 819810-93-0/BI OR 819810-94-1/BI OR 819810-95-2/BI OR
819810-96-3/BI OR 819810-97-4/BI OR 819810-98-5/BI OR 819810-99
-6/BI OR 819811-00-2/BI OR 819811-01-3/BI OR 819811-02-4/BI OR
819811-03-5/BI OR 819811-04-6/BI OR 819811-05-7/BI OR 819811-06
-8/BI OR 819811-07-9/BI OR 819811-08-0/BI OR 819811-09-1/BI OR
819811-10-4/BI OR 819811-11-5/BI OR 819811-12-6/BI OR 819811-13
-7/BI OR 819811-14-8/BI OR 819811-15-9/BI OR 819811-16-0/BI OR
819811-17-1/BI OR 819811-18-2/BI OR 819811-19-3/BI OR 819811-

L23 220 SEA ABB-ON L22 AND L11

L24 254 SEA ABB-ON L11 AND N/ELS

FILE 'ZCAPLUS' ENTERED AT 14:57:24 ON 15 JUN 2007

L25 74 SEA ABB-ON L24

FILE 'REGISTRY' ENTERED AT 14:57:42 ON 15 JUN 2007

L26 191 SEA ABB-ON L24 AND 5-c

FILE 'ZCAPLUS' ENTERED AT 14:57:48 ON 15 JUN 2007

L27 39 SEA ABB-ON L26

FILE 'REGISTRY' ENTERED AT 14:58:02 ON 15 JUN 2007

L28 52 SEA ABB-ON L26 NOT L22

L29 15175 SEA ABB-ON NITROBENZ

L30 52 SEA ABB-ON L28 NOT L29

L31 0 SEA ABB-ON L28 AND L29

L32 118258 SEA ABB-ON NITROBENZ

L33 11 SEA ABB-ON L28 NOT L32
D SCAN

FILE 'ZCAPLUS' ENTERED AT 15:01:47 ON 15 JUN 2007

L34 12 SEA ABB-ON L33

FILE 'REGISTRY' ENTERED AT 15:02:33 ON 15 JUN 2007

L35 STR L4

L36 9 SEA SUB=L11 SSS SAM L35

L37 0 SEA ABB-ON L36 NOT L22

L38 STR L4

L39 STR L4

L40 9 SEA SUB=L11 SSS SAM (L35 OR L36 OR L39)

D QUE

L41 193 SEA SUB=L11 SSS FUL (L35 OR L36 OR L39) EXTEND

L42 151 SEA SUB=L11 SSS FUL (L35 OR L36 OR L39)
SAVE TEMP L42 HAV415SUB/A

FILE 'CAPLUS' ENTERED AT 15:05:38 ON 15 JUN 2007

L43 5 SEA ABB-ON L42

L44 1 SEA ABB-ON L21 OR (L21 AND L43)

D SCAN

L45 29025 SEA ABB-ON HEAT SHOCK/OBI OR HSP90/OBI OR HSP/OBI

L46 283 SEA ABB-ON L11

L47 283 SEA ABB-ON L11

100

L48 1 SEA ABB-ON L47 AND L45
L49 166137 SEA ABB-ON ANTITUMOR AGENTS/CT
L50 484200 SEA ABB-ON NEOPLAS7/OBI
L51 8 SEA ABB-ON L47 AND (L49 OR L50)

FILE 'CAPLUS' ENTERED AT 15:08:14 ON 15 JUN 2007
D QUE NOS L44
D IBIB ED ABS HITSTR L44

FILE 'REGISTRY' ENTERED AT 15:08:48 ON 15 JUN 2007
D STAT QUE L11

FILE 'CAPLUS' ENTERED AT 15:08:48 ON 15 JUN 2007
D QUE NOS L48
D QUE NOS L51

L52 7 SEA ABB-ON (L48 OR L51) NOT L44
D IBIB ED ABS HITSTR 1-7

FILE 'REGISTRY' ENTERED AT 15:09:42 ON 15 JUN 2007
D STAT QUE L42

FILE 'CAPLUS' ENTERED AT 15:09:42 ON 15 JUN 2007
D QUE NOS L43

L53 3 SEA ABB-ON L43 NOT (L44 OR L52)
D IBIB ED ABS HITSTR 1-3

FILE 'HOME' ENTERED AT 15:10:23 ON 15 JUN 2007
D STAT QUE L42

>>

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	5	("7115651" "7074770").pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 13:36
S2	6	"561415".ap.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/13 08:55
S3	2	"7022700".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/20 17:27
S4	7	"309527".ap.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/20 17:32
S5	2	"6495560".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/20 17:33
S6	2	"5523456".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/20 17:33